Publications by authors named "Ghaith Mitri"
Article Synopsis
- A study was done to see if a treatment called extracorporeal photopheresis (ECP) plus standard care was better for patients with a disease called chronic graft-versus-host disease (cGVHD).
- The study included 60 adult patients who were split into two groups: one got ECP with standard care, and the other just got standard care.
- After 28 weeks, more patients who received ECP responded positively to the treatment, and their quality of life stayed the same, unlike those who only received standard care.
The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). To investigate real-world use of ECP in CTCL patients in the US. Data from the Truven MarketScan database (2010-2015) were used to create a cohort of CTCL patients receiving systemic treatment.
View Article and Find Full Text PDFPurpose: Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA). The study estimates pharmacy and medical cost budgetary impacts of wider adoption by US payers of febuxostat, a urate-lowering therapy (ULT) for the treatment of gout.
Methods: A US payer-perspective budget impact model followed ULT patients from a 1,000,000-member plan over 3 years.
Background: Patients with chronic kidney disease (CKD) are at increased risk for developing gout and having refractory disease. Gout flare prevention relies heavily on urate-lowering therapies such as allopurinol and febuxostat, but clinical decision making in patients with moderate-to-severe CKD is complicated by significant comorbidity and the scarcity of real-world cost-effectiveness studies.
Objective: To compare total and disease-specific health care expenditures by line of therapy in allopurinol and febuxostat initiators after diagnosis with gout and moderate-to-severe CKD.
Objective: To determine the cost-effectiveness of febuxostat vs allopurinol for the management of gout.
Methods: A stochastic microsimulation cost-effectiveness model with a US private-payer perspective and 5-year time horizon was developed. Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence.
Objective: To compare anti-Th/To-positive and anticentromere antibody (ACA)-positive patients with limited cutaneous systemic sclerosis (lcSSc).
Methods: We reviewed the medical records of 107 anti-Th/To-positive patients and 365 ACA-positive patients who were first evaluated during 1985-2000. ACA was detected by indirect immunofluorescence on HEp-2 cell substrate, and anti-Th/To was detected by RNA immunoprecipitation with K562 cell extracts.